London, July 4, 2026, 20:04 (BST)
- Craneware closed Friday at 1,082p, down 26.0%, after cutting its FY26 outlook.
- The new FY26 guidance points to revenue and adjusted EBITDA close to FY25 levels, not the growth path flagged earlier in the year.
- About 7.4% of issued shares changed hands on Friday, based on reported volume and Craneware’s June share count.
- Chair Will Whitehorn bought 640 shares at 1,173p on the day of the warning.
Craneware plc LON:CRW lost about £130 million of equity value on Friday after the healthcare software group said delayed 340B drug activity and pushed-out enterprise contracts would leave full-year revenue and profit below market expectations. London markets were closed on Saturday, so the fall stands as the last traded price for the week.
The stock closed at 1,082p, down 380p, or 26.0%, from Thursday’s 1,462p close. Reported volume was 2.52 million shares, equal to about 7.4% of Craneware’s AIM securities in issue. That is the sharper investor point: a near-flat earnings reset triggered heavy churn in a stock with only 34.24 million shares in issue, excluding treasury shares.
| Market read-through | Friday data |
|---|---|
| Previous close | 1,462p |
| Friday close | 1,082p |
| One-day change | -380p / -26.0% |
| Shares traded | 2.52 million |
| Shares traded as % of issued shares | about 7.4% |
| Implied market value erased | about £130 million |
The company said FY26 revenue would be $205 million to $208 million and adjusted EBITDA $65 million to $67 million. At the midpoints, that is $206.5 million of revenue and $66.0 million of adjusted EBITDA, only 0.4% and 1.1% above FY25, respectively. FY25 revenue was $205.7 million and adjusted EBITDA was $65.3 million.
| Measure | FY25 actual | FY26 latest guidance midpoint | Change |
|---|---|---|---|
| Revenue | $205.7 mln | $206.5 mln | +0.4% |
| Adjusted EBITDA | $65.3 mln | $66.0 mln | +1.1% |
| FY25 adjusted EBITDA margin | 32% | about 32% implied | broadly flat |
Craneware said the shortfall came from slower conversion of identified 340B opportunities into recognised revenue, plus a small number of significant enterprise contracts now expected to contribute in FY27. It said outstanding 340B qualifying drug purchases were about $500 million, but revenue is booked when customers receive the benefit from eligible drugs, not when opportunities are identified.
Chief Executive Keith Neilson said he was “disappointed” and that the “long-term opportunity remains intact”. He said pharmacy market complexity had hurt the year, while customer retention and cash generation remained high. Investegate
The warning cuts against the first-half tone. In March, Craneware reported H1 FY26 revenue up 6% to $105.7 million and adjusted EBITDA up 10% to $33.4 million, with net revenue retention at 103%. The July update leaves the second half carrying little visible growth on a full-year basis.
A Capital Access Group note published after the update said it had reduced forecasts in line with guidance and viewed the 340B shortfall as mainly a timing issue tied to a pause in U.S. drug policy, rather than a major change in the market opportunity. It cut its discounted cash-flow valuation by 5% to 2,945p, still more than double Friday’s closing price.
Craneware Chair Will Whitehorn bought 640 shares at 1,173p on Friday, worth £7,507.20. The closing price was still 7.8% below his purchase price, a small insider buy set against a much larger market repricing.
The valuation gap is stark against last year’s takeover history. Reuters reported in June 2025 that Craneware rejected Bain Capital’s £26.50-per-share proposal, which would have valued the company at about £939.4 million, saying it undervalued the business. Friday’s 1,082p close is about 59% below that rejected price.
For the week ahead, no Craneware event is listed on MarketScreener’s calendar, while Fidelity lists final results for September 2026. The next test is whether brokers treat the 340B issue as a one-year delay or apply a lower multiple to revenue tied to drug-purchase timing.
